Imperial College London
Portrait Picture

DrCandiceRoufosse

Faculty of Medicine, Department of Immunology and Inflammation

Clinical Reader in Renal Pathology
 
 
 
//

Contact

 

+44 (0)20 3313 3280c.roufosse

 
 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Nikolopoulou:2019,
author = {Nikolopoulou, A and Condon, M and Turner-Stokes, T and Cook, HT and Duncan, N and Galliford, J and Levy, J and Lightstone, L and Pusey, C and Roufosse, C and Cairns, T and Griffith, M},
journal = {BMC Nephrology},
pages = {1--9},
title = {Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis: A randomised controlled trial.},
url = {https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-019-1539-z},
volume = {20},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background: Tacrolimus (TAC) is effective in treating membranous nephropathy (MN);however relapses are frequent after treatment cessation. We conducted a randomisedcontrolled trial to examine whether the addition of mycophenolate mofetil (MMF) to TACwould reduce relapse rate.Methods: 40 patients with biopsy proven idiopathic MN and nephrotic syndrome wererandomly assigned to receive either TAC monotherapy (n=20) or TAC combined with MMF(n=20) for 12 months. When patients had been in remission for 1 year on treatment the MMFwas stopped and the TAC gradually withdrawn in both groups over 6 months. Patients alsoreceived supportive treatment with angiotensin blockade, statins, diuretics andanticoagulation as needed. Primary endpoint was relapse rate following treatmentwithdrawal. Secondary outcomes were remission rate, time to remission and change in renalfunction.Results: 16/20 (80%) of patients in the TAC group achieved remission compared to 19/20(95%) in the TAC/MMF group (p=0.34). The median time to remission in the TAC groupwas 54 weeks compared to 40 weeks in the TAC/MMF group (p=0.46). There was nodifference in the relapse rate between the groups: 8/16 (50%) patients in the TAC grouprelapsed compared to 8/19 (42%) in the TAC/MMF group (p=0.7). The addition of MMF toTAC did not adversely affect the safety of the treatment.Conclusions: Addition of MMF to TAC does not alter the relapse rate of nephrotic syndromein patients with MN.
AU  - Nikolopoulou,A
AU  - Condon,M
AU  - Turner-Stokes,T
AU  - Cook,HT
AU  - Duncan,N
AU  - Galliford,J
AU  - Levy,J
AU  - Lightstone,L
AU  - Pusey,C
AU  - Roufosse,C
AU  - Cairns,T
AU  - Griffith,M
EP  - 9
PY  - 2019///
SN  - 1471-2369
SP  - 1
TI  - Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis: A randomised controlled trial.
T2  - BMC Nephrology
UR  - https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-019-1539-z
UR  - http://hdl.handle.net/10044/1/72815
VL  - 20
ER  -
Download